AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
Research context
AFT Pharmaceuticals Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
AFT Pharmaceuticals Limited is currently in a long term downtrend where the price is trading 3.6% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.5.
AFT Pharmaceuticals Limited's total revenue rose by 4.0% to $49M since the same quarter in the previous year.
Its net income has dropped by 88.0% to $1M since the same quarter in the previous year.
Finally, its free cash flow fell by 141.2% to $-1M since the same quarter in the previous year.
Based on the above factors, AFT Pharmaceuticals Limited gets an overall score of 2/5.